Sanofi Receives EMA Orphan Designation For Efdoralprin Alfa
I'm PortAI, I can summarize articles.
Sanofi announced that the European Medicines Agency (EMA) has granted orphan designation to efdoralprin alfa, an investigational drug for treating alpha-1 antitrypsin deficiency-related emphysema. This designation highlights the unmet medical need and potential of the drug. Previously, the US FDA granted fast track and orphan drug designation for the same condition. Efdoralprin alfa is in clinical development, with safety and efficacy yet to be evaluated. Sanofi plans to present data at an upcoming medical meeting and engage with global regulatory authorities.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments